menu

ReachMD

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

A Cohort Study of Cervical Screening Using Partial HPV Typing and Cytology Triage

    A Cohort Study of Cervical Screening Using Partial HPV Typing and Cytology Triage Mark Schiffman, Noorie Hyun, Tina R. Raine-Bennett, Hormuzd Katk...
    • Sponsored by

    • Overview

      A Cohort Study of Cervical Screening Using Partial HPV Typing and Cytology Triage

      Mark Schiffman, Noorie Hyun, Tina R. Raine-Bennett, Hormuzd Katki, Barbara Fetterman, Julia C. Gage, Li C. Cheung, Brian Befano, Nancy Poitras, Thomas Lorey, Philip E. Castle and Nicolas Wentzensen

      Int J Cancer. 2016 Dec 1;139(11):2606-15. doi: 10.1002/ijc.30375. Epub 2016 Aug 26.

      Abstract 

      HPV testing is more sensitive than cytology for cervical screening. However, to incorporate HPV tests into screening, risk-stratification ("triage") of HPV-positive women is needed to avoid excessive colposcopy and overtreatment. We prospectively evaluated combinations of partial HPV typing (Onclarity, BD) and cytology triage, and explored whether management could be simplified, based on grouping combinations yielding similar 3-year or 18-month CIN3+ risks. We typed ∼9,000 archived specimens, taken at enrollment (2007-2011) into the NCI-Kaiser Permanente Northern California (KPNC) HPV Persistence and Progression (PaP) cohort. Stratified sampling, with reweighting in the statistical analysis, permitted risk estimation of HPV/cytology combinations for the 700,000+-woman KPNC screening population. Based on 3-year CIN3+ risks, Onclarity results could be combined into five groups (HPV16, else HPV18/45, else HPV31/33/58/52, else HPV51/35/39/68/56/66/68, else HPV negative); cytology results fell into three risk groups ("high-grade," ASC-US/LSIL, NILM). For the resultant 15 HPV group-cytology combinations, 3-year CIN3+ risks ranged 1,000-fold from 60.6% to 0.06%. To guide management, we compared the risks to established "benchmark" risk/management thresholds in this same population (e.g., LSIL predicted 3-year CIN3+ risk of 5.8% in the screening population, providing the benchmark for colposcopic referral). By benchmarking to 3-year risk thresholds (supplemented by 18-month estimates), the widely varying risk strata could be condensed into four action bands (very high risk of CIN3+ mandating consideration of cone biopsy if colposcopy did not find precancer; moderate risk justifying colposcopy; low risk managed by intensified follow-up to permit HPV "clearance"; and very low risk permitting routine screening.) Overall, the results support primary HPV testing, with management of HPV-positive women using partial HPV typing and cytology.

    • Commercial Support

      This activity is supported by an independent educational grant from BD Life Sciences.

    Facebook Comments

    You must be in to display playlists.

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.